Yuan Jiao, Yang Yan-Li, Zhao Ya-Lin, Xu Yu-Wei, Wang Lei, Gao Jin-Fang
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences; Tongji Shanxi Hospital, No.99 Longcheng Street, Taiyuan, 030032, Shanxi, China.
Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases(Rheumatic diseases), Taiyuan, China.
Stem Cell Res Ther. 2025 Aug 26;16(1):457. doi: 10.1186/s13287-025-04597-8.
Interstitial lung disease (ILD) is a common complication associated with connective tissue disease (CTD). It is characterized by a progressive decline in lung function, significantly affecting prognosis and potentially leading to respiratory failure or even death. The primary pathological mechanisms behind ILD include abnormal immune system activation and pulmonary fibrosis. Current treatment options primarily include immunosuppressive agents, antifibrotic drugs, and oxygen therapy to alleviate symptoms. However, these treatments have notable limitations, including individual variability and uncertain long-term effectiveness, which pose significant challenges in managing CTD-associated ILD (CTD-ILD).In recent years, Mesenchymal Stromal Cells (MSCs) have gained considerable attention as a promising therapeutic option for CTD-ILD. This is due to their immunomodulatory, antifibrotic, and tissue repair properties. Both clinical and preclinical studies have shown the therapeutic potential of MSCs in this context. However, this article also discusses the challenges and limitations of MSC-based therapies, highlighting the need for further clinical studies to validate their effectiveness.
间质性肺疾病（ILD）是结缔组织病（CTD）常见的并发症。其特征为肺功能进行性下降，严重影响预后，并可能导致呼吸衰竭甚至死亡。ILD背后的主要病理机制包括免疫系统异常激活和肺纤维化。目前的治疗选择主要包括免疫抑制剂、抗纤维化药物和氧疗以缓解症状。然而，这些治疗存在显著局限性，包括个体差异和长期疗效不确定，这给CTD相关ILD（CTD-ILD）的管理带来了重大挑战。近年来，间充质基质细胞（MSC）作为CTD-ILD一种有前景的治疗选择受到了广泛关注。这是由于它们具有免疫调节、抗纤维化和组织修复特性。临床和临床前研究均显示了MSC在这方面的治疗潜力。然而，本文也讨论了基于MSC疗法的挑战和局限性，并强调需要进一步的临床研究来验证其有效性。
